Insomnia drug approved for extended use

Circadin is a synthetic version of melatonin, the sleep-inducing hormone produced by the pineal gland
Circadin is a synthetic version of melatonin, the sleep-inducing hormone produced by the pineal gland

Circadin (melatonin) can now be prescribed for up to 13 weeks. It was previously approved only as a 3-week course of treatment.

The 2mg prolonged-release tablet is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients aged 55 or over.

In a study in this setting, a subgroup of patients aged between 65 and 80 years fell asleep significantly more quickly following treatment with prolonged-release melatonin for up to 26 weeks, than after receiving placebo.

View Circadin drug record

Further information: Lundbeck


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases